Larimar Therapeutics, Inc.

NASDAQ:LRMR

7.36 (USD) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182017201620152014
Revenue 0000000000
Cost of Revenue 0.3110.2720.3260.1550.0780.2610.1880.2120.070
Gross Profit -0.311-0.272-0.326-0.155-0.078-0.261-0.188-0.212-0.070
Gross Profit Ratio 0000000000
Reseach & Development Expenses 27.6724.2538.39631.40720.7949.52941.73939.77454.61827.391
General & Administrative Expenses 14.08812.27612.06911.3972.4241.51712.1618.28919.1958.141
Selling & Marketing Expenses 14.074000012.93-0.212-1.153-0.070
SG&A 14.08812.27612.06911.3972.42412.93211.94817.13619.1258.141
Other Expenses 01.171-0.1710.3220.08200000
Operating Expenses 41.75836.52650.46542.80423.21462.46153.68756.9173.74335.532
Operating Income -41.758-36.526-50.465-42.804-23.214-62.722-53.875-57.122-73.813-35.532
Operating Income Ratio 0000000000
Total Other Income Expenses Net 4.8091.171-0.1710.3220.082-0.2460.947-1.056-0.473-1.038
Income Before Tax -36.949-35.355-50.636-42.482-23.132-62.968-52.928-58.178-74.286-36.57
Income Before Tax Ratio 0000000000
Income Tax Expense 0-1.171-0.326-0.155-0.094-1.6-0.9-0.3-0.9460
Net Income -36.949-34.184-50.31-42.327-23.132-61.368-52.028-57.878-74.286-36.57
Net Income Ratio 0000000000
EPS -0.84-1.33-2.93-3.56-2.51-22.85-22.76-25.44-33.32-15.14
EPS Diluted -0.84-1.33-2.93-3.56-2.51-22.85-22.76-25.44-33.32-15.14
EBITDA -41.447-36.526-50.465-42.804-23.136-62.461-53.687-56.91-73.743-35.532
EBITDA Ratio 0000000000